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Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active RET kinase
inhibitor. In the phase I/II trial, selpercatinib demonstrated clinically meaningful antitumor activity with
manageable toxicity in heavily pre-treated and treatment-naive patients with RET-mutant medullary
thyroid cancer (MTC). LIBRETTO-531 (NCT04211337) is a multicenter, open-label, randomized, controlled,
phase III trial comparing selpercatinib to cabozantinib or vandetanib in patients with advanced/metastatic
RET-mutant MTC. The primary objective is to compare progression-free survival (per RECIST 1.1) by blinded
independent central review of patients with progressive, advanced, multikinase inhibitor-naive, RETmutant MTC treated with selpercatinib versus cabozantinib or vandetanib. Key secondary objectives are
to compare other efficacy outcomes (per RECIST 1.1) and tolerability of selpercatinib versus cabozantinib
or vandetanib.
Plain language summary: Selpercatinib (also known by the brand name RetevmoR /RetsevmoR ) is a new
treatment available in multiple countries for people with advanced or metastatic RET-mutant medullary
thyroid cancer (MTC). Thyroid cancer starts in your thyroid gland and may spread or metastasize to other
parts of the body, including lungs, bones, and occasionally the brain, which means the cancer is likely to
be advanced. Advanced thyroid cancer can be driven by a gene in your body, one of which is RET. This is a
summary of the LIBRETTO-531 study which compares selpercatinib, which is a strong and selective inhibitor
of RET, with two approved drugs, cabozantinib and vandetanib. Patients with advanced or metastatic RETmutant MTC who have not already received treatment with kinase inhibitors are being enrolled. This trial
will evaluate how long people during and after treatment live with the disease without it getting worse.
Selpercatinib may affect both healthy cells and tumor cells, which can result in side effects, which will also
be evaluated in this study. This study is active and currently recruiting new patients.
Clinical Trial Registration: NCT04211337 (ClinicalTrials.gov)
First draft submitted: 27 June 2022; Accepted for publication: 27 July 2022; Published online:
15 August 2022
Keywords: medullary thyroid cancer • phase III trial • RET alteration • RET kinase inhibitor • RET mutation

• selpercatinib • targeted therapy

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from parafollicular C cells [1].
MTC occurs in hereditary (25%) and sporadic forms (75%) [2,3]. Germline mutations in the rearranged during
transfection (RET) proto-oncogene have been identified in hereditary conditions. For example, multiple endocrine
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neoplasia (MEN) 2A and MEN2B [2,3]. Germline-activating RET mutations are found in 95% to 98% of hereditary
MTC, and somatic RET mutations are present in more than half the cases of sporadic MTC [4,5]. In patients with
advanced and progressive MTC, the prevalence of somatic RET mutations was found to be up to 86% [6].
The pathogenesis of MTC is closely related to the activation of the RET proto-oncogene, both in hereditary [7–10]
and in sporadic cases [5,11,12]. The RET proto-oncogene encodes a transmembrane receptor tyrosine kinase that is
constitutively activated through two primary mechanisms: point mutations that directly or indirectly activate the
kinase, and chromosomal rearrangements leading to the fusion of RET to a 5 upstream partner [4,13,14]. Codon
634 mutation (p.C634R) in exon 11 is described as the most common substitution RET mutation in MEN2A
syndrome patients [15]. Kinase domain mutation p.M918T is described as the most common mutation in MEN2B
syndrome patients and in sporadic MTC patients [15]. RET-mutated MTC is associated with more aggressive
disease and poorer prognosis, and consequently tumors in a majority of patients with metastatic MTC harbor
RET mutations [3,5]. National Comprehensive Cancer Network guidelines recommend germline RET testing for all
patients diagnosed with MTC and somatic RET testing in patients who are RET germline unknown or negative [16].
The clinical course of MTC is highly heterogeneous, varying from indolent tumors that remain unchanged for
many years to aggressive cancers associated with high mortality [17,18]. Initial treatment of MTC depends on its
clinical presentation. Although surgery can be curative for patients who present with localized disease, approximately
50% of all patients diagnosed with MTC develop recurrent disease [19]. Metastatic MTC remains incurable.
Until recently, only two multikinase inhibitors (MKI), cabozantinib and vandetanib, had received regulatory
approval for advanced MTC (irrespective of the presence or absence of a RET mutation), with tumor response
rates of 28 and 45% and progression-free survival (PFS) improvements (over placebo) of 7.2 and 11.2 months,
respectively [20,21]. However, the efficacy of these MKIs is ultimately limited by incomplete inhibition of RET,
significant toxicity from more potent inhibition of other targets (e.g., KDR/VEGFR2, EGFR, MET) and poor
pharmacokinetics (i.e., significant drug accumulation and long half-life contributing to toxicity but not efficacy).
As a result, most patients treated with these agents experience significant toxicities requiring dose interruptions,
reductions (35% with vandetanib, 79% with cabozantinib), and/or treatment cessation (12% with vandetanib,
16% with cabozantinib) [20,21]. Additionally, some RET disease-causing variants are non-responsive to MKI therapy,
in other words, nonspecific RET inhibitor therapy. Thus, highly selective RET inhibitors have been developed to
improve the efficacy and safety profile compared with MKIs. Selpercatinib [22–24] and pralsetinib [25–27] are two
currently approved small molecule RET inhibitors.

Selpercatinib

Selpercatinib is a first-in-class highly selective and potent RET kinase inhibitor with nanomolar potency against wild
type RET and RET alterations including M918T, MKI resistance-associated V804M, and others [28]. Selpercatinib
showed robust and durable efficacy with a favorable safety profile in patients with advanced or metastatic RETdriven treatment-naive and previously treated cancers, irrespective of prior therapy [22,29–31]. Based on these findings,
selpercatinib is approved in multiple countries for the treatment of RET-altered thyroid and lung cancers [24,32].
The phase I/II LIBRETTO-001 clinical trial demonstrated the safety and efficacy of selpercatinib in patients
with RET-mutant MTC [22,23,33]. Treatment with selpercatinib resulted in a 69% objective response rate (ORR)
(95% CI: 61–77%) by blinded independent central review (BICR) in patients previously treated with cabozantinib
and/or vandetanib (n = 143) [33]. At a median follow-up of 17.5 months, 76% of responses were ongoing. In
cabozantinib/vandetanib-naive patients with RET-mutant MTC, treatment with selpercatinib resulted in a 71%
ORR (95% CI: 62–80%) by BICR (n = 112). At a median follow-up of 9.3 months, 94% of responses were
ongoing.
At the updated data-cut of March 2020, the majority of adverse reactions were grade 1 or 2. Grades 3–4 events
occurring in ≥2% of patients included hypertension (20%), increased ALT level (7%), increased AST level (6%),
diarrhea (4%), prolonged QT corrected interval (4%), headache (2%) and abdominal pain (2%). Discontinuation
rates were low with 2% of patients discontinuing due to treatment-related adverse events. The safety profile was
similar to the overall safety profile for all patients who received selpercatinib, regardless of tumor type.
The LIBRETTO-531 clinical trial

LIBRETTO-531 (also referred to as J2G-MC-JZJB [JZJB]) is a multicenter, open-label, randomized, controlled,
phase III trial comparing selpercatinib to cabozantinib or vandetanib in patients with advanced/metastatic RET-
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n = 250–400
Study endpoints

Stratification factors:
Mutation status: (M918T vs other)
Investigator’s choice of treatment if randomized to
Arm B, with declared intent prior to randomization

Primary endpoint:

PFS per RECIST 1.1 by BICR

Key secondary endpoint:

TFFS by BICR, comparative tolerability, PFS and TFFS by investigator, ORR
and DOR by BICR and investigator, OS, PFS2 by investigator

Figure 1. LIBRETTO-531 study design.
BICR: Blinded independent committee review; BID: Twice daily; DOR: Duration of response; MKI: Mulitkinase inhibitor; ORR: Objective
response rate; OS: Overall survival; PD: Progressive disease; PFS: Progression-free survival; PFS2: Progression after the next line of therapy;
QD: Once daily; RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1; TFFS: Treatment failure free survival, which
incorporates radiographic PD, unacceptable toxicity (predefined by protocol) or death.

mutant MTC (NCT04211337), naive to any prior kinase inhibitor therapy. This study is active and recruiting
participants, with initial planned enrollment of 250 patients at approximately 160 sites in 21 countries. Sample
size re-estimation based on comparative data will be conducted at the interim efficacy analysis. The total number
of patients could be increased from 250 up to a maximum of approximately 400, depending on the results of the
interim efficacy analysis.
Although the LIBRETTO-001 phase I/II trial demonstrated that selpercatinib can produce high rates of
objective responses that are durable in both MKI pretreated and MKI-naive MTC patients, it remains important
to confirm these results and better understand the benefit of selpercatinib in the context of other available first-line
treatments for advanced/metastatic MTC. This will be a key consideration for approval and reimbursement in
many countries around the world. Furthermore, the study evaluates key secondary end points, including treatment
failure-free survival (TFFS) and comparative tolerability, which could further characterize the potential benefits of
selpercatinib relative to the current standard of care MKI inhibitors [34].
Study design

This phase III study is a head-to-head comparison of selpercatinib versus physician’s choice of cabozantinib or
vandetanib in patients with advanced or metastatic MTC. The study includes a screening phase, an on-study
treatment phase with an optional crossover treatment phase (only arm B patients), and a post-treatment follow-up
phase (Figure 1). During the screening phase, baseline patient characteristics and eligibility criteria will be assessed
using medical history, physical exam, clinical labs and tumor evaluations. Prior to enrollment, the presence of the
RET gene alteration must be confirmed in a tumor, germline DNA or blood sample. An unstained, archived tumor
tissue sample in a quantity sufficient to allow for retrospective central analysis confirmation of RET mutation status
is required. Patients will be stratified by RET mutation (M918T vs other) and intended treatment if randomized
to arm B (cabozantinib vs vandetanib). The selection of cabozantinib or vandetanib for each eligible patient is
required by the investigator prior to randomization. Treatment will continue until disease progression, development
of unacceptable toxicity, the start of a new anticancer therapy, withdrawal of patient consent, death, or completion
of the study. Patients who were randomized to arm B who have radiographic disease progression confirmed by
BICR may be eligible for crossover to selpercatinib if they meet the eligibility criteria.
The post-treatment phase includes a short-term follow-up period that begins once the patient and investigator
decide the patient will end study therapy. Long-term follow-up begins when the patient completes the (30 ± 7 days)
short-term follow-up period and ends with the patient’s death, upon study withdrawal, upon loss to follow-up, or
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Table 1. Study objectives.
Objectives

End points

Primary
To compare PFS of patients with progressive, advanced, kinase inhibitor-naive,
RET-mutant MTC treated with selpercatinib vs cabozantinib or vandetanib

• PFS by BICR

Secondary
To compare other efficacy outcomes, based on
RECIST 1.1 criteria, observed in patients with
progressive, advanced, kinase inhibitor-naive,
RET-mutant MTC treated with selpercatinib vs
cabozantinib or vandetanib

• TFFS by BICR
• TFFS by investigator
• PFS by investigator
• ORR by investigator and BICR
• DOR by investigator and BICR
• OS
• PFS2 by investigator

To evaluate the safety and tolerability of selpercatinib compared with
cabozantinib or vandetanib

• Safety per CTCAE v5.0 (including but not limited to): incidence and severity of
TEAEs, SAEs, deaths, and clinical laboratory abnormalities

To compare the tolerability of selpercatinib vs cabozantinib or vandetanib

• Proportion of time with high side-effect bother based on FACT-GP5

To assess/evaluate performance of local RET laboratory tests compared with a
single, central test

• RET mutation status

To assess the pharmacokinetics of selpercatinib in patients receiving selpercatinib

• Predose plasma concentrations at Day 8 of Cycle 1, and at Day 1 of Cycles 2
through 6

BICR: Blinded independent committee review; DOR: Duration of response; FACT-GP5: Functional Assessment of Cancer Therapy general scale to assess overall side effect burden; MTC:
Medullary thyroid cancer; ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival; PFS2: Progression after the next line of therapy; SAE: Serious adverse event;
TEAE: Treatment-emergent adverse event; TFFS: Treatment failure free survival, which incorporates radiographic disease progression, unacceptable toxicity (predefined by protocol) or
death.

upon study completion. To evaluate patient reported health outcomes (quality of life, patient functioning, health
status, disease symptoms and toxicities) patient-reported surveys will be administered.
Objectives & end points

The study objectives are detailed in Table 1. The primary objective is to compare PFS (per RECIST 1.1) by BICR.
PFS by BICR will act as a gatekeeper for the key secondary end point of TFFS by BICR, in other words, this key
secondary end point will be tested conditionally on achieving a statistical significance for the primary end point.
TFFS incorporates radiographic progressive disease, unacceptable toxicity (predefined by protocol) or death, of
patients with progressive, advanced, kinase inhibitor naive, RET-mutant MTC treated with selpercatinib versus
cabozantinib or vandetanib. TFFS was selected as this end point takes into account potential improvement in
both efficacy and toxicity profile relative to comparator agents. Additional secondary end points are comparative
tolerability, investigator-assessed PFS, investigator-assessed TFFS, investigator- and BICR-assessed ORR/duration
of response, overall survival, investigator-assessed progression after the next line of therapy, safety/tolerability and
pharmacokinetics of selpercatinib.
Key eligibility criteria

Key eligibility criteria are summarized in Table 2 and below. To be eligible for the trial, participants must have
histologically or cytologically confirmed unresectable, locally advanced/metastatic MTC, a RET gene alteration,
documented RECIST 1.1 progression within 14 months by BICR, measurable disease per RECIST 1.1, an Eastern
Cooperative Oncology Group performance status of 0 to 2, a life expectancy of at least 3 months, adequate organ
function, and the ability to swallow capsules. Exclusion criteria include: presence of additional validated oncogenic
drivers in MTC, having received prior systemic treatment with kinase inhibitor(s), taking a concomitant medication
that is known to cause QTc prolongation, or having symptomatic central nervous system involvement, or active
cardiovascular disease.
Dose & schedule of therapy

Patients in Arm A will receive selpercatinib at a starting dose of 160 mg twice daily. Patients in Arm B will receive
cabozantinib at a starting dose of 140 mg once daily (QD) or vandetanib at a starting dose of 300 mg QD.
All treatments are administered orally, and a cycle is defined as 28 days in length, regardless of treatment arm
assignment. Treatment will continue until radiographic disease progression, unacceptable toxicity, withdrawal of
consent or death. Dosing and treatment durations for all intervention groups are outlined in Table 3.
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Table 2. Key eligibility criteria for LIBRETTO-531.
Inclusion criteria

Exclusion criteria

Locally advanced or metastatic MTC
◦ Histologically confirmed, unresectable locally advanced or metastatic disease
and no prior history of treatment with kinase inhibitors for advanced/metastatic
disease
Patient characteristics
◦ Age ≥12, where allowed
◦ Documented RECIST 1.1 progression within 14 months by BICR
◦ Measurable disease by RECIST 1.1
◦ ECOG performance status of 0–2
◦ Adequate organ function
◦ Able to swallow capsules
◦ Not pregnant/agreeable to highly effective birth control/no breastfeeding
RET alteration
◦ RET mutation identified via local NGS or PCR testing on germline DNA, tumor or
blood
◦ Sufficient tissue for central analysis of RET mutation

Medical conditions
◦ An additional validated oncogenic driver in MTC
◦ Symptomatic CNS metastases, leptomeningeal carcinomatosis, or untreated spinal
cord compression
◦ Clinically significant active cardiovascular disease or history of myocardial
infarction within 6 months prior to planned start of study treatment or
prolongation of the QT interval corrected for heart rate using Fridericia’s formula
(QTcF) ⬎470 msec on more than one ECG during screening
◦ Active uncontrolled systemic bacterial, viral or fungal infection or serious ongoing
intercurrent illness, such as hypertension or diabetes, despite optimal treatment
(screening for chronic conditions is not required)
◦ Clinically significant active malabsorption syndrome or other condition likely to
affect gastrointestinal absorption of the study drug.
◦ Active hemorrhage or at significant risk for hemorrhage
Prior/Concomitant Therapy
◦ Prior systemic treatment with kinase inhibitor(s)
◦ Are taking a concomitant medication that is known to cause QTc prolongation
Prior/Concurrent Clinical Study Experience
◦ Have participated, within the last 30 days (4 months for studies conducted in
Japan; 3 months for studies conducted in the UK), in a clinical study involving an
investigational product

BICR: Blinded independent committee review; CNS: Central nervous system; ECOG: Eastern Cooperative Oncology Group; MTC: Medullary thyroid cancer; NGS: Next-generation sequencing; PCR: Polymerase chain reaction; RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1.

Table 3. Doses and dosing schedule.
Intervention

Arm A (selpercatinib)

Arm B (investigator’s discretion of B1: cabozantinib or B2: vandetanib)
Vandetanib†

Selpercatinib

Cabozantinib

Dose

160 mg

140 mg

300 mg

Schedule

BID continuously in 28-day cycles

QD continuously in 28-day cycles

QD continuously in 28-day cycles

Route

Oral

Oral

Oral

dose of vandetanib for patients with creatinine clearance ⬍50 ml/min is 200 mg QD.
BID: Twice daily; QD: Once daily.
† Starting

Efficacy evaluations

All patients are required to undergo imaging at baseline and subsequent serial imaging at disease assessment time
points. Scans should be obtained within 28 days of baseline and every 8 weeks after treatment initiation through
week 24, and every 12 weeks thereafter until progression, the start of a new anticancer therapy, death, or study
completion. The BICR will conduct assessment of tumor response by RECIST 1.1.
Safety evaluations

For each patient, safety assessments including physical examination, vital signs, electrocardiogram and clinical
laboratory tests will be evaluated at predefined intervals. Adverse events will be continuously evaluated throughout
the duration of the study.
Conclusion
The LIBRETTO-531 phase III trial outlined here will evaluate selpercatinib versus cabozantinib or vandetanib
in patients with advanced/metastatic RET-mutant MTC. The findings of this study will help further define the
benefit of selpercatinib used as first-line therapy in patients with RET-mutant MTC, naive to prior kinase inhibitor
therapy.
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Executive summary
Background
• Medullary thyroid carcinoma (MTC) is a rare malignancy of the thyroid that accounts for 5–10% of all thyroid
malignancies.
• Germline-activating RET mutations are found in 95–98% of hereditary MTC, and somatic RET mutations are
present in >50% of the cases of sporadic MTC.
• Multikinase inhibitors (MKI) with anti-RET activity have limited efficacy due to incomplete inhibition and
significant toxicity.
Selpercatinib
• Selpercatinib, a first-in-class highly selective and potent RET kinase inhibitor, is approved in multiple countries for
the treatment of RET-altered lung or thyroid cancers.
• Selpercatinib has nanomolar potency against wild type RET and RET alterations including M918T, MKI
resistance-associated V804M, and others.
• In the LIBRETTO-001 phase I/II trial, selpercatinib treatment demonstrated clinically meaningful responses and
sustained antitumor activity with a manageable toxicity profile in both heavily pre-treated and treatment-naive
patients with RET-mutant MTC.
LIBRETTO-531 study
• The global, multicenter, open-label, randomized, controlled, phase III LIBRETTO-531 trial, will evaluate
selpercatinib versus cabozantinib or vandetanib in patients with MKI-naive locally advanced or metastatic
RET-mutant MTC (NCT04211337).
• First ever randomized Phase III clinical trial in patients with MKI treatment naive RET-mutant MTC.
Conclusion
• The results of this key trial will help further define the role of selpercatinib as a front-line treatment for people
living with advanced or metastatic RET-mutant MTC.

Supplementary data
An infographic accompanies this paper. To view or download this infographic in your browser please click here:
https://www.futuremedicine.com/doi/suppl/10.2217/fon-2022-0657
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